ArticleScientific reports2025
Implantation of a vaccine platform for extended antigen release (VPEAR) induces long-term immunity against Haemonchus contortus in sheep.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Catalytically Active Recombinant Cysteine Proteases ofInternational journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The nematode Haemonchus contortus causes severe anemia in sheep and goats. Drug-resistant isolates are common, prompting a need for parasite control measures beyond chemotherapeutics. Vaccination is one promising approach for mitigation of clinical signs associated with haemonchosis. One challenge for H. contortus vaccine efforts is the need to administer repeated boosting doses at regular intervals. In this study, we evaluated a vaccine platform for extended antigen release (VPEAR) designed to initiate and maintain long-term immunity following a single immunization event in sheep. We compared a soluble vaccine depot with montanide adjuvant to the VPEAR platform with two different adjuvant combinations. Vaccination with VPEAR adjuvanted with DEAE-dextran induced antibody titers in 5 out of 6 vaccinated sheep up to 47 weeks post-vaccination. Challenge experiments revealed a 73% decrease in adult worm burden in this vaccine group compared to adjuvant alone and serum antibodies from these animals bound the luminal surface of the parasite intestine. Overall, the VPEAR platform was effective for long-term vaccination with no indication of immune tolerance to the parasite upon challenge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.